Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

06. September 2024 16:03 ET | Quelle: NurExone Biologic Inc

NurExone Demonstrates Extended Therapeutic Window of ExoPTEN Post Spinal-Cord Injury in Preclinical Study

NurExone demonstrates a longer timeframe of ExoPTEN treatment can be effectively administered post Spinal-Cord Injury
15. August 2024 16:03 ET | Quelle: NurExone Biologic Inc

NurExone Biologic Achieves Key Milestone in Support of Robust Exosome Manufacturing Process

NurExone’s reliable production from diverse biological sources allows NurExone to optimize exosome production with consistency and efficiency
09. August 2024 16:04 ET | Quelle: NurExone Biologic Inc

NurExone's ExoPTEN, loaded with siRNA, Demonstrates Ability to Target Injury and Inflammation Sites – New Study

NurExone announces promising new data for its ExoPTEN nanodrug, highlighting progress towards commercial-grade manufacturing
13. April 2021 16:35 ET | Quelle: Inotiv, Inc.

Inotiv, Inc. Enhances Histopathology Offering with Announcement of Agreement to Purchase HistoTox Labs, Inc.

WEST LAFAYETTE, Ind., April 13, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of nonclinical and analytical contract research...